Sensitivity, Specificity, and Low Cost: Keys for the Clinical Implementation of CTCs Detection
Speakers: María Jose Serrano, PhD, Hospital Universitario Virgen de las Nieves, and...
Liquid Biopsy
Spotlight NGS Panels
Ultra-sensitive somatic mutation detection from liquid biopsy samples
Designed specifically for detection of mutations from liquid biopsy samples, Spotlight Oncology Panels are turnkey solutions for Illumina sequencers, offering ultra-sensitive variant detection from low input quantities of DNA. The high sensitivity of Spotlight panels makes them ideal for cfDNA and CTCs.
Spotlight NGS Panels
All-in-one liquid biopsy panel for ultra-sensitive variant detection from cfDNA
Designed specifically for detection of somatic mutations from liquid biopsy samples, the Spotlight 59 Oncology Panel is a turnkey solution for Illumina sequencers, offering ultra-sensitive variant detection from low input quantities of DNA. Spotlight 59 is a pan-cancer panel covering 59 relevant genes. The high sensitivity of Spotlight 59 makes it ideal for cfDNA, CTCs, and other challenging sample types. Combined with ERASE-Seq, Fluxion’s statistically powered variant caller, Spotlight 59 delivers >90% sensitivity and <0.1 false positives at 0.1% allele frequency. Compatible with cfDNA and CTCs from Fluxion’s IsoFlux Liquid Biopsy System, Spotlight 59 creates a complete sample-to-answer assay for high sensitivity mutation detection of solid tumor cancers from blood samples.
Panel includes:
59 gene oncology panel for Illumina sequencers
Complete kit that includes primers and indexed sequencing adapters. High sensitivity (2 reaction tubes per sample)
Processes 24 samples
Includes ERASE-Seq desktop application and cloud-based data analysis
FEATURES
The Spotlight 59 Oncology Panel offers comprehensive and hotspot coverage of 59 clinically-relevant oncology-related genes, using a 277-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms.
- Accurate detection to 0.05% VAF and below
- Turnkey solution for library generation in a single kit, including sequencing adapters and sample indexes
- Ready-to-sequence libraries in just 2 hours
- Starting input quantities as low 20 ng total DNA
- Average amplicon size of 140 bp for compatibility with cfDNA and FFPE
- ERASE-Seq cloud-based variant calling included with kit purchase
- No UMIs (molecular IDs) required; increases sensitivity, reduces bias and assay complexity
- No primer trimming required
Comprehensive coverage of all coding regions of TP53
The Spotlight TP53 liquid biopsy NGS panel contains 21 amplicons with an average size of 140 bp that provides comprehensive coverage of all coding regions of TP53. The Spotlight TP53 Panel is compatible with short DNA fragments from cfDNA and FFPE samples. This product is a complete kit that includes all elements necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters. Combined with ERASE-Seq, Fluxion’s statistically powered variant caller, Spotlight TP53 delivers >90% sensitivity and <0.1 false positives at 0.1% allele frequency. Compatible with cfDNA and CTCs from Fluxion’s IsoFlux Liquid Biopsy System, Spotlight TP53 creates a complete sample-to-answer assay for high sensitivity mutation detection of solid tumor cancers from blood samples.
Panel includes:
Panel with complete coverage of TP53 coding regions for Illumina sequencers
Complete kit that includes primers and indexed sequencing adapters. High sensitivity (2 reaction tubes per sample)
Processes 24 samples
Includes cloud-based ERASE-Seq data analysis
FEATURES
Spotlight TP53 is powered by ERASE-Seq, Fluxion’s statistically powered variant caller that is available free of charge to Spotlight users. ERASE-Seq utilizes statistical analysis to compare sequencing results to a detailed background model and technical replicates. This approach eliminates both random errors and systemic biases inherent in all sequencing workflows.
- >90% sensitivity and <0.1 false positives per sample at 0.05-0.1% allele frequency
- Turnkey solution for library generation in a single kit, including sequencing adapters and sample barcodes
- Ready-to-sequence libraries in just 2 hours
- Starting input quantities as low 20 ng total DNA
- Average amplicon size of 140 bp for compatibility with cfDNA and FFPE
- ERASE-Seq cloud-based variant calling included with kit purchase
- Custom configurations available to target specific variants
- No UMIs (molecular IDs) required; increases sensitivity, reduces bias and assay complexity
Contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS
The Spotlight EGFR Liquid Biopsy Panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight EGFR Pathway Panel is compatible with short DNA fragments from both cfDNA and FFPE samples. This panel is especially well-suited for research focused on detecting clinically-relevant allele variants in DNA from cell-free DNA (cfDNA) and circulating tumor cells (CTCs).
Panel includes:
Panel with continuous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS for Illumina sequencers
Complete kit that includes primers and indexed sequencing adapters. High sensitivity (2 reaction tubes per sample)
Processes 24 samples
Includes cloud-based ERASE-Seq data analysis
FEATURES
The Spotlight EGFR Liquid Biopsy Panel is a complete kit that includes all elements necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters for Illumina sequencers. Combined with ERASE-Seq, Fluxion’s statistically powered variant caller, Spotlight EGFR delivers >90% sensitivity and <0.1 false positives at 0.1% allele frequency.
- >90% sensitivity and <0.1 false positives per sample at 0.05-0.1% allele frequency
- Turnkey solution for library generation in a single kit, including sequencing adapters and sample barcodes • Ready-to-sequence libraries in just 2 hours
- Starting input quantities as low 20 ng total DNA
- Average amplicon size of 136 bp for compatibility with cfDNA and FFPE
- ERASE-Seq cloud-based variant calling included with kit purchase
- Custom configurations available to target specific variants
- No UMIs (molecular IDs) required; increases sensitivity, reduces bias and assay complexity
Comprehensive and exon-level hotspot coverage of 23 clinically relevant myeloid genes
The Spotlight Myeloid Panel combines content from peer-reviewed publications and other sources to offer comprehensive and exon-level hotspot coverage of 23 clinically-relevant genes implicated in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). Because of the high prevalence of myeloid variants in clonal hematopoiesis of indeterminate potential (CHIP) studies, this is an ideal panel for uncovering CH variants in either cell-derived or cell-free DNA samples.
Panel includes
23 gene myeloid liquid biopsy panel for Illumina sequencers
Complete kit that includes primers and indexed sequencing adapters
Processes 24 samples
Includes cloud-based ERASE-Seq data analysis
FEATURES
The Spotlight Myeloid Panel offers robust performance on cfDNA and FFPE samples starting with as little as 20 ng input. Compatible with all Illumina platforms, the panel has highly sensitive detection of rare variants down to 0.1% allele frequency, with sequence ready libraries in just 2 hours. Fluxion offers streamlined, free analysis of the panel via Fluxion’s ERASE-Seq Variant Caller.
- Covers over 12,000 COSMIC and 1,900 ClinVar mutations and generates targeted libraries compatible with Illumina® sequencing platforms
- Provides full exon coverage of TP53 with flanking intron/exon boundaries
- Simultaneous detection of single nucleotide variants (SNV) and small insertion and deletions (indels), all within a fast and easy single-tube assay workflow
- Add your own targets using our pre-validated primers or others content
Stand out amongst the crowd. Develop your own custom panel.
Designed specifically for detection of somatic mutations from liquid biopsy samples, Spotlight custom panels are turnkey solutions for Illumina sequencers, offering ultra-sensitive variant detection from low input quantities of DNA. The high sensitivity of Spotlight custom panels make them ideal for cfDNA, CTCs, and other challenging sample types. Combined with ERASE-Seq, Fluxion’s statistically powered variant caller, Spotlight custom panels deliver >90% sensitivity and <0.1 false positives at 0.1% allele frequency. Compatible with cfDNA and CTCs from Fluxion’s IsoFlux Liquid Biopsy System, Spotlight custom panels create a complete sample-to-answer assay for high sensitivity mutation detection of solid tumor cancers from blood samples.
Contact us to get 25% discount on your first order
FEATURES
Fluxion offers customized Spotlight Panels optimized to enable fast, comprehensive targeted sequencing. Combined with ERASE-Seq bioinformatics, this unique approach provides a powerful solution for detecting ultra-low frequency somatic mutations using low-input DNA from cfDNA. To get started with a custom Spotlight panel, fill out the custom panel design form and submit to info@fluxionbio.com.
- Detection to <0.05% allele frequency
- Average specificity >99.999%
- Ready-to-sequence libraries in just 2 hours
- Starting input quantities as low as 10 ng DNA
- Average amplicon size of 140 bp for compatibility with cfDNA and FFPE
- No molecular barcodes (unique molecular IDs) required; increases sensitivity, reduces bias and assay complexity
Resources Library & Support
Visit our library of application notes, webinars, live demos, posters and publications.
For additional support, customers can access our support site for operation technical guides, cell culture optimizations, software updates, pre-recorded training, and troubleshooting guides.
Latest Webinars
Enhanced Analytical Techniques for Molecular Characterization of CTCs and cfDNA
Speakers: Jeff Jensen, CEO, Fluxion Biosciences
About This Presentation
This...
How to Detect ARV7 mRNA in PBMCs and CTCs to Predict Chemotherapy Response in Prostate Cancer
Speakers: Mercedes Marín-Aguilera, PhD, Research Fellow, Institut d'Investigacions...